Alpha DNA Investment Management LLC Trims Stock Position in Boston Scientific Co. (NYSE:BSX)

Alpha DNA Investment Management LLC decreased its holdings in Boston Scientific Co. (NYSE:BSX) by 12.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,078 shares of the medical equipment provider’s stock after selling 1,245 shares during the quarter. Alpha DNA Investment Management LLC’s holdings in Boston Scientific were worth $811,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. M&T Bank Corp increased its stake in shares of Boston Scientific by 0.3% in the 3rd quarter. M&T Bank Corp now owns 106,127 shares of the medical equipment provider’s stock worth $8,894,000 after purchasing an additional 370 shares in the last quarter. Passumpsic Savings Bank bought a new stake in Boston Scientific during the third quarter valued at about $3,015,000. World Investment Advisors LLC raised its stake in shares of Boston Scientific by 50.9% in the third quarter. World Investment Advisors LLC now owns 11,684 shares of the medical equipment provider’s stock worth $979,000 after buying an additional 3,939 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Boston Scientific during the 3rd quarter valued at about $1,175,000. Finally, Tidal Investments LLC grew its stake in shares of Boston Scientific by 8.8% during the 3rd quarter. Tidal Investments LLC now owns 86,507 shares of the medical equipment provider’s stock valued at $7,249,000 after acquiring an additional 6,990 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 4,675 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the sale, the executive vice president now owns 28,454 shares of the company’s stock, valued at $2,966,329.50. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now directly owns 5,502 shares in the company, valued at approximately $560,103.60. This represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 133,183 shares of company stock worth $13,948,476. 0.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

BSX has been the topic of several analyst reports. UBS Group lifted their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 7th. Truist Financial dropped their target price on shares of Boston Scientific from $120.00 to $113.00 and set a “buy” rating for the company in a report on Friday, April 11th. Needham & Company LLC raised Boston Scientific from a “hold” rating to a “buy” rating and set a $113.00 price target on the stock in a report on Wednesday. Wells Fargo & Company boosted their price objective on Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Finally, Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research report on Friday, January 10th. One analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $110.22.

Boston Scientific Trading Down 0.2 %

Shares of NYSE BSX opened at $95.08 on Friday. Boston Scientific Co. has a 1-year low of $66.80 and a 1-year high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The business’s 50 day moving average is $99.68 and its two-hundred day moving average is $94.26. The stock has a market capitalization of $140.63 billion, a P/E ratio of 76.06, a PEG ratio of 2.79 and a beta of 0.73.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.